Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.84 |
| ▸ | RAF1 | P04049 | 11/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.82 |
| ▸ | RET | P07949 | 3/20 | 0.82 |
| ▸ | BRAF | P15056 | 3/20 | 0.82 |
| ▸ | GSK3B | P49841 | 2/20 | 0.82 |
| ▸ | ARAF | P10398 | 2/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | HTR1A | P08908 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | KIT | P10721 | 2/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.82 |
| ▸ | FLT1 | P17948 | 2/20 | 0.82 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737847 | 0.91 | KDR (1.00) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL13471761 | 0.90 | RAF1 (0.84) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL4209263 | 0.90 | RAF1 (0.82) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL13471762 | 0.90 | RAF1 (0.84) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL2480623 | 0.90 | RAF1 (0.84) | KDRRAF1PDGFRBRETBRAF | |
| Sorafenib SCHEMBL14739751 | 0.90 | RAF1 (1.00) | KDRRAF1PDGFRBRETBRAF | |
| Sorafenib SCHEMBL29349634 | 0.90 | RAF1 (1.00) | KDRRAF1PDGFRBRETBRAF | |
| Sorafenib SCHEMBL8218 | 0.90 | RAF1 (1.00) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL29918250 | 0.90 | RAF1 (1.00) | KDRRAF1PDGFRBRETBRAF | |
| SCHEMBL548133 | 0.90 | RAF1 (1.00) | KDRRAF1PDGFRBRETBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | claimed |
| EP-1603879-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | claimed |
| WO-2004078128-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2020163598-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | CDK4, MKI67, TP53 | KDR 135/4885RAF1 761/4885PDGFRB 585/4885 |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | CDK4, MKI67, TP53 | KDR 135/4885RAF1 761/4885PDGFRB 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.